DOCSLIB.ORG

Spotlight on Market Access Actionable Understandings from AIS Health’S In-Depth Coverage

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Spotlight on Market Access Actionable Understandings from AIS Health’S In-Depth Coverage Spotlight on Market Access Actionable understandings from AIS Health’s in-depth coverage September 16, 2019 Recent Situations Stress That Data Is More Important Than Ever to FDA, Drug Uptake 2 Clinical Trials by Indication: Q2 2019 A pair of drugmakers and the FDA found themselves in the news lately, but it’s safe to say it wasn’t for the reasons they would prefer. Both situations Reality Check: PCSK9 Inhibitors 8 stress the importance of data needed to secure product approvals, and, per- haps, payer and provider uptake. On Aug. 6, the FDA put out a statement addressing “data accuracy issues” with Zolgensma (onasemnogene abeparvovec-xioi), a new gene ther- apy to treat spinal muscular atrophy in people less than 2 years old who have bi-allelic mutations in the survival motor neuron 1 gene, including those who are presymptomatic when diagnosed. The one-time therapy has the distinction of being the most expensive drug in the world, with a price tag of $2.1 million. The FDA approved the drug from AveXis, Inc. on May 24 (SMA 7/1/19, p. 6). On June 28, AveXis — which was acquired by Novartis AG last year — notified the agency that there was “a data manipulation issue that impacts the accuracy of certain data from product testing performed in animals sub- mitted in the biologics license application (BLA) and reviewed by the FDA.” continued on p. 3 Report Reveals That Almost 100 RM/AT Products Are in Phase III Clinical Trials This past quarter saw two new gene therapies: Novartis AG subsidiary AveXis, Inc.’s Zolgensma (onasemnogene abeparvovec-xioi) received FDA approval May 24 for the treatment of spinal muscular atrophy (SMA 7/1/19, p. 6), and bluebird bio’s Zynteglo (autologous CD34+ cells encoding βA-T87Q- globin gene) received conditional marketing authorization from the Europe- an Commission for transfusion-dependent beta thalassemia. While only a handful of therapies in the broader regenerative medicine/ advanced therapy (RM/AT) space are available globally, a new report shows that is likely to change, as there are more than 1,000 products in the pipe- line. Many of these therapies truly are innovative products, but they don’t come cheap and often have complex reimbursement schemes that some pay- ers and providers are struggling with, an issue that will need to be handled soon as more of these therapies are poised to hit the market. © Managed Markets Insight & Technology, LLC | 1 MMIT’s Spotlight on Market Access September 16, 2019 The Alliance for Regenerative Medicine published ◊ 249 cell therapy trials are proceeding: 49 the report, titled Quarterly Global Regenerative Med- are in Phase I, 168 are in Phase II, and 32 are in icine Sector Report: Q2 2019, on Aug. 1. It shows there Phase III. are 1,069 clinical trials using specific RM/AT technol- ◊ 44 tissue engineering trials are happen- ogies, which include gene therapy, gene-modified cell ing: five are in Phase I, 23 are in Phase II, and 16 therapy, cell therapy and tissue engineering. Ninety- are in Phase III. four of those products are in Phase III trials. They also span a variety of indications (see chart More specifically, the report reveals: below). ◊ 366 gene therapy clinical trials are un- While Zolgensma’s $2.125 million price for a derway: 117 are Phase I, 219 are Phase II, and one-time infusion makes it the costliest drug on the 30 are Phase III. planet, other newer RM/AT products are certainly ◊ 410 gene-modified cell therapy trials are not cheap. Spark Therapeutics Inc.’s Luxturna (vore- ongoing: 187 are in Phase I, 207 are in Phase II, tigene neparvovec-rzyl), approved in December 2017 and 16 are in Phase III. for a rare form of blindness, costs $425,000 per eye; Clinical Trials by Indication: Q2 2019 • 643 (60%) of all current clinical trials are in oncology, including leukemia, lymphoma, and cancers of the brain, breast, bladder, cervix, colon, esophagus, ovaries, pancreas, and others. • 60 (6%) are in cardiovascular disorders, including congestive heart failure, myocardial infarction, critical limb ischemia, heart disease, and others. • 57 (5%) are in diseases of the central nervous system, including multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, traumatic brain injury, ALS, and others. SOURCE: Alliance for Regenerative Medicine, Quarterly Global Regenerative Medicine Sector Report: Q2 2019, released August 2019. Download the report at https://alliancerm.org/?smd_process_download=1&download_id=4962. © Managed Markets Insight & Technology, LLC. Contact [email protected]. | 2 MMIT’s Spotlight on Market Access September 16, 2019 Novartis Pharmaceuticals Corp.’s chimeric antigen not in place to have the ability to track the patient once receptor T-cell (CAR-T) therapy Kymriah (tisagenlec- therapy is administered.” leucel), first approved in August 2017, costs $475,000 Download the report at https://bit.ly/31cvh6W. G or $373,000 depending on the type of cancer it’s used in; and Gilead Sciences, Inc. unit Kite Pharma, Inc.’s by Angela Maas Yescarta (axicabtagene ciloleucel), approved in October This story was reprinted from AIS Health’s monthly 2017 to treat large B-cell lymphoma, costs $373,000. publication RADAR on Specialty Pharmacy. For more Many of these products’ manufacturers are offering information, visit https://aishealth.com/product/ various reimbursement schemes, including rebates if a specialty-pharmacy. therapy doesn’t work, other outcomes-based deals and multiyear pay-over-time payment options. But experts Issues Stress Data’s Importance note that many barriers to successfully executing these continued from p. 1 deals exist. According to a July 26 memorandum by Wilson “In principle, spreading the cost over a five-year W. Bryan, M.D., director of the FDA’s Office of Tissues period and putting the cost installments at risk based and Advanced Therapies, “AveXis appears to have upon efficacy is a good approach,” says Winston Wong, become aware of the data manipulation as early as Pharm.D., president of W-Squared Group, about March 14, 2019,” but rather than informing the agency, Zolgensma. “However, the devil is in the details. Do we which was evaluating Zolgensma’s BLA at the time, the have the systems in place that have the capability to company first conducted its own internal investigation, administer a five-year contract?” reporting its findings to the FDA after the investigation was completed. Had the FDA known of the issue before “In principle, spreading the cost over it approved Zolgensma, “I believe that the approval would have been delayed” beyond its Prescription Drug a five-year period and putting the cost User Fee Act (PDUFA) date of May 31, he wrote, add- installments at risk based upon efficacy ing that he believed the FDA still would have approved is a good approach.” the BLA. “Based on the information available at this time, In addition, he asks, “Who is responsible for the the Phase 3 clinical trial results continue to provide billing of the installment, and who is actually making compelling evidence of the effectiveness of Zolgensma, the annual payment? Is it the insurance carrier in all along with sufficient evidence of safety to support an cases, or is that passed on to the self-funded employer? overall favorable benefit-risk profile,” wrote Bryan. Under the payment installment option, how does the “It is the manufacturer’s responsibility to sub- provider, who has to obtain the product, get reim- mit complete and accurate information in marketing bursed?” applications for evaluation by the FDA. If we become According to Wong, “We do not have the systems aware of a concern with data submitted to the agency in place to handle the tracking and processing of as part of our review of a product application, it is in installment billing over a period of five years, as well the best interest of patients, their caregivers, and the as having the ability to track patients once they have public that we disclose such information, to the extent left the health plan,” which “will be a major obstacle permitted by law,” said the FDA in its statement. It to overcome for any value-based agreement where said that it “remains confident that Zolgensma should payment will be dependent upon continued efficacy remain on the market.” of the therapy. From the manufacturer perspective, a However, the agency said, it is “carefully assessing value-based contract implies that no payment would be this situation” and could “take action, if appropriate, made if the patient relapses or passes on. Systems are which may include civil or criminal penalties.” Accord- © Managed Markets Insight & Technology, LLC. Contact [email protected]. | 3 MMIT’s Spotlight on Market Access September 16, 2019 ing to Bryan’s memo, “a complete assessment of the through all appropriate criminal, civil, and regulato- impact of the data manipulation will require additional ry actions against the company. Anything short of a investigation, discussions both internally within CBER forceful response would signal a green light to future [i.e., the FDA’s Center for Biologics Evaluation and pharmaceutical behavior.” The situation, they wrote, Research] and with AveXis, will probably require that “smacks of the pharmaceutical industry’s privilege and AveXis submit and FDA review one or more BLA sup- greed.…It is an outrage that after knowingly misleading plements, and may take at least several months.” the FDA in a rush to make a profit,” Novartis in its Aug. In response to the FDA statement, Novartis issued 6 press release refused “to acknowledge any culpability a press release Aug. 6 that read, in part, “we maintain or remorse. Instead, the company doubled down on its that the totality of the evidence demonstrating the greed-driven behavior.” product’s effectiveness and its safety profile continue to provide compelling evidence supporting an overall favorable benefit-risk profile.
Load more

Recommended publications
  • Curriculum Vitae
    Curriculum Vitae PERSONAL INFORMATION Ulrike Schara WORK EXPERIENCE 1991- 1997 Education in Paediatrics Paediatric Outpatient Centre,City Hospital Gelsenkirchen. (Germany) Paediatric Outpatient Centre. City Hospital Gelsenkirchen.<br/>Childrens Hospital, Ruhr University Bochum<br/> 1998- 2002 Senior Neuropediatrics Children&apos;s University Hospital Bochum (Germany) . 2002- 2003 Head of Neuropediatrics Children&apos;s University Hospital Bochum (Germany) 2004- 2006 Head of Neuropediatrics Children&apos;s Hospital, City of Neuss (Germany) 2007- Present Head of the Neuropaediatric Outpatient Centre and Consultant for Neuropaediatrics University of Essen (Germany) EDUCATION AND TRAINING 1991- 2012 MD, Professor Ruhr University of Bochum, Germany University of Essen (Germany) ADDITIONAL INFORMATION Expertise Publications Publcations of the past 5 years 1.Rudnik-Schöneborn S, Tölle D, Senderek J, Eggermann K, Elbracht M, Kornak U, von der Hagen M, Kirschner J, Leube B, Müller-Felber W, Schara U, von Au K, Wieczorek D, Bußmann C, Zerres K. Diagnostic algorithms in Charcot-Marie-Tooth neuropathies: experiences from a German genetic laboratory on the basis of 1206 index patients. Clin Genet. 2016 Jan;89(1):34-43 2.Byrne S, Jansen L, U-King-Im JM, Siddiqui A, Lidov HG, Bodi I, Smith L, Mein R, Cullup T, Dionisi-Vici C, Al-Gazali L, Al-Owain M, Bruwer Z, Al Thihli K, El-Garhy R, Flanigan KM, Manickam K, Zmuda E, Banks W, Gershoni-Baruch R, Mandel H, Dagan E, Raas-Rothschild A, Barash H, Filloux F, Creel D, Harris M, Hamosh A, Kölker S, Ebrahimi-Fakhari D, Hoffmann GF, Manchester D, Boyer PJ, Manzur AY, Lourenco CM, Pilz DT, Kamath A, Prabhakar P, Rao VK, Rogers RC, Ryan MM, Brown NJ, McLean CA, Said E, Schara U, Stein A, Sewry C, Travan L, Wijburg FA, Zenker M, Mohammed S, Fanto M, Gautel M, Jungbluth H.
    [Show full text]
  • Immunoprophylaxis of Influenza Using AAV Vector Delivery of Cross
    Immunoprophylaxis of Influenza using AAV Vector Delivery of Cross-Subtype Neutralizing Single Domain Antibodies JOANNE MARIE M. DEL ROSARIO Thesis submitted for the degree of Doctor of Philosophy Infection and Immunity University College London 2020 To Chris, as fate would have it. To Teki, thank you for everything. 2 DECLARATION I, Joanne Marie M. Del Rosario, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. __________________________ 3 ABSTRACT Cross-subtype neutralizing single domain antibodies against influenza present new opportunities for immunoprophylaxis and pandemic preparedness. Their simple modular structure and single open reading frame format are highly amenable to gene therapy-mediated delivery. R1a-B6, an alpaca-derived single domain antibody (nanobody), that is capable of potent cross-subtype neutralization in vitro of H1N1, H5N1, H2N2, and H9N2 influenza viruses, through binding to a highly conserved epitope in the influenza hemagglutinin stem region, was previously described. To evaluate the potential of R1a-B6 for immunoprophylaxis via adeno-associated viral (AAV) vector delivery, it was reformatted as Fc fusions of mouse IgG1 (ADCC-) and IgG2a (ADCC+) isotypes. This is also to extend R1a-B6’s half-life and to assess the requirement for ADCC for efficacy of R1a-B6 in vitro and in vivo. It was found that reformatted R1a-B6 of either mouse IgG isotype retained its potent binding and neutralization activity against different Group I influenza A subtypes in vitro. The findings in this study also demonstrate that a single intramuscular injection in mice of AAV encoding R1a-B6-Fc was able to drive sustained high-level expression (0.5–1.1 mg/mL) of the nanobody-Fc in sera with no evidence of reduction for up to 6 months.
    [Show full text]
  • Innovationsreport 2020 Kurzfassung
    Innovationsreport 2020 Auswertungsergebnisse von Routinedaten der Techniker Krankenkasse aus den Jahren 2017 bis 2018 Herausgeber: Gerd Glaeske Erstellt mit freundlicher Unterstützung der Techniker Krankenkasse (TK) 3 Herausgeber Prof. Dr. Gerd Glaeske Experten für ausgewählte Kapitel Prof. Dr. med. Janbernd Kirschner, Bonn Prof. Dr. med. Dieter Ukena, Bremen Prof. Dr. med. Barbara Schmalfeldt, Hamburg Prof. Dr. med. Wolfgang Schramm, München Autoren Prof. Dr. med. Karl Broich, Dr. Stanislava Dicheva‐Radev, Dörte Fuchs, Prof. Dr. Gerd Glaeske, Dr. Marion Haberkamp, Dr. Iris Hinneburg, Friederike Höfel, Prof. Dr. Janbernd Kirschner, Dr. Wiebke Löbker, Anja Lübs, Dr. André S. Morawetz, Lutz Muth, Dr. Frauke Naumann‐Winter, Linda Richter, Saskia Ritter, Dr. Kristin Sauer, Dr. Birgit Schindler unter Mitarbeit von Esra Aksoy, Friederike Höfel, Berit Marquardt, Linda Richter, Marle Wilhelm Anschrift: Universität Bremen, SOCIUM, Mary‐Somerville‐Str. 5, 28359 Bremen Aus Gründen der besseren Lesbarkeit wurde auf die Nennung beider geschlechtsspezifischer Formen verzichtet. Im Allgemeinen ist aber das jeweils andere Geschlecht ebenfalls gemeint. 2 Glossar .......................................................................................... 7 Vorwort zum Innovationsreport 2020 ...........................................15 Vorwort des Herausgebers ............................................................17 1 Einleitung ................................................................................19 2 Ziele und Methodik..................................................................33
    [Show full text]
  • Zolgensma, INN-Onasemnogene Abeparvovec
    26 March 2020 EMA/200482/2020 Committee for Medicinal Products for Human Use (CHMP) Committee for Advanced Therapies (CAT) Assessment report Zolgensma International non-proprietary name: onasemnogene abeparvovec Procedure No. EMEA/H/C/004750/0000 Note The CAT Assessment report has been endorsed by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ...................................................................................... 6 1.2. Steps taken for the assessment of the product ......................................................... 9 2. Scientific discussion .............................................................................. 10 2.1. Problem statement ............................................................................................. 10 2.1.1. Disease or condition ......................................................................................... 10 2.1.2. Epidemiology .................................................................................................. 11 2.1.3.
    [Show full text]
  • Med Pharm PA List to Build Pdfs.Xlsx
    The following medications, typically administered in a provider's office or ambulatory/outpatient infusion center, require authorization prior to utilization. Authorization requests can be submitted via the Portal. Additionally, you are welcome to call our member services line to initiate the Prior Authorization process. This list is updated quaterly. Effective date: 1/1/2021 Therapeutic category Brand Name Generic Name HCPCS Immunologic agent Orencia, IV infusion abatacept J0129 Botulinum toxins Dysport abobotulinumtoxin B J0586 HER-2 receptor drug Kadcyla ado-trastuzumab emtansine J9354 Ophthalmic injectable Eylea afilbercept J0178 Enzyme replacement drug Fabrazyme agalsidase beta J0180 Multiple sclerosis drug Lemtrada alemtuzumab J0202 Enzyme replacement drug Lumizyme alglucosidase alfa J0221 Enzyme replacement drug Strensiq asfotase alfa J3590 (non-specific) PD1-PDL1 drug Tecentriq atezolizumab J9022 PD1-PDL1 drug Bavencio avelumab J9023 CAR-T Therapy Yescarta axicabtageneciloleucel inpatient admin Systemic lupus erythematosus (SLE) drug Benlysta belimumab J0490 Antineoplastic agent Beleodaq belinostat J9032 Antineoplastic Belrapzo bendamustine HCl J9036 Antineoplastic Bendeka bendamustine HCl J9034 Antineoplastic agent Treanda bendamustine HCl J9033 Respiratory injectable Fasenra benralizumab J0517 J9035/J3590 (ophthalmology Antineoplastic Avastin bevacizumab uses this non-specific code) Antineoplastic agent Mvasi bevacizumab-awwb Q5107 Antineoplastic agent Zirabev bevacizumab-bvzr Q5118 Antineoplastic agent Blincyto blinatumomab
    [Show full text]
  • Virtual Posters
    VIRTUAL POSTERS Poster # Title Primary Author First Name Primary Author Last Name City State Brain Tumors/OnCology 200 Clinical and Molecular Features of Atypical Pediatric Neurocytoma: A Case Series Adam Kalawi San Diego CA 201 Atypical molecular features of pediatric tectal glioma: A single institutional series Maayan Yakir San Diego CA 202 Hypercalcemia in Use of the Ketogenic Diet for Treatment of Spinal Lipoma Lila Worden Hartford CT Cognitive/Behavioral Disorders (inCluding Autism) 203 The neurodevelopmental profile of HIVEP2-related disorder Alisa Mo Boston MA 204 Burden of disease in a rare neurologic disorder: caregiver’s perspective on Aicardi Goutières Syndrome Francesco Gavazzi Philadelphia PA 205 Diagnosis delay in Aicardi Goutières Syndrome: a parents’ perspective Francesco Gavazzi Philadelphia PA 206 Validation of the telemedicine application of the Gross Motor Function Measure-88 Francesco Gavazzi Philadelphia PA 207 Altered Cerebellar White Matter in Sensory Processing Dysfunction Is Associated With Impaired Multisensory Integration and Attention Elysa Marco San Rafael CA 208 A comparison of the adaptive and autistic behavior in three developmental epileptic encephalopathies – SLC6A1, SCN2A, STXBP1 Kimberly Goodspeed Dallas TX 209 Spatial topography of cross-frequency coupling during NREM sleep is disrupted in Rett Syndrome Patrick Davis Boston MA 210 Serotonin transporter genotype predicts adaptive behavior outcomes in children with autism Kevin Shapiro Los Angeles CA 211 Clinical and Numerical presentation of Neurocognitive
    [Show full text]
  • Pharmacotherapy of Spinal Muscular Atrophy (SMA), 5.01.574
    PHARMACY / MEDICAL POLICY – 5.01.574 Pharmacotherapy of Spinal Muscular Atrophy (SMA) Effective Date: Nov. 1, 2020 RELATED MEDICAL POLICIES: Last Revised: Jan. 31, 2021 None Replaces: N/A Select a hyperlink below to be directed to that section. POLICY CRITERIA | DOCUMENTATION REQUIREMENTS | CODING RELATED INFORMATION | EVIDENCE REVIEW | REFERENCES | HISTORY ∞ Clicking this icon returns you to the hyperlinks menu above. Introduction Spinal muscular atrophy (SMA) is a rare disease that leads to muscle weakness and atrophy. SMA affects the muscles of the limbs and trunk. SMA is caused by changes to the survival motor neuron 1 gene (SMN1). This gene creates a protein called the survival motor neuron (SMN) protein. Too little of the SMN protein leads to muscle weakness that gets worse over time and muscles that waste away (atrophy). There are different types of SMA. Type 1 SMA, also known as Werdnig-Hoffman disease or infantile SMA, is the most severe form. Symptoms usually start before 6 months of age. The chance of survival to one year of age is 50 percent. Less severe forms are Type 2, also known as Dubowitz disease, and Type 3, or Kugelberg-Welander disease. Evrysdi™ (risdiplam), Spinraza® (nusinersen), and Zolgensma® (onasemnogene abeparvovec- xioi) are three treatments the Food and Drug Administration has approved for SMA. This policy discusses when the use of Evrysdi™, Spinraza®, and Zolgensma® may be considered medically necessary. Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals.
    [Show full text]
  • Aetna PA Info
    Procedures, programs and drugs that require precertification Participating provider precertification list Starting June 1, 2021 Applies to the following plans (also see General information section #1-#4, #9-#10): Aetna® plans, except Traditional Choice® plans All health benefits and insurance plans offered and/or underwritten by Innovation Health plans, Inc., and Innovation Health Insurance Company, except indemnity plans, Foreign Service Benefit Plan, MHBP and Rural Carrier Benefit Plan All health benefits and health insurance plans offered, underwritten and/or administered by the following: Banner Health and Aetna Health Insurance Company and/or Banner Health and Aetna Health Plan Inc. (Banner|Aetna), Texas Health +Aetna Health Insurance Company and/or Texas Health+Aetna Health Plan Inc. (Texas Health Aetna), Allina Health and Aetna Health Insurance Company (Allina Health| Aetna), Sutter Health and Aetna Administrative Services LLC (Sutter Health | Aetna) Aetna.com 23.03.882.1 R (6/21) For more information, read all general precertification guidelines Providers may submit most precertification requests electronically through the secure provider website or using your Electronic Medical Record (EMR) system portal. (See #1 in the General Information section for more information on precertification.) Services that require precertification: 1. Inpatient confinements (except hospice) 18. Nonparticipating freestanding ambulatory For example, surgical and nonsurgical stays, surgical facility services, when referred by stays in a skilled nursing facility or rehabilitation a participating provider facility, and maternity and newborn stays that 19. Orthognathic surgery procedures, bone exceed the standard length of stay (LOS). (See grafts, osteotomies and surgical #6 in the General Information section.) management of the temporomandibular 2. Ambulance joint Precertification required for transportation by 20.
    [Show full text]
  • Issue Brief. Gene Therapy in 2019: Milestones and Challenges
    PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE WWW.PCORI.ORG | [email protected] | FOLLOW US @PCORI 1828 L STREET NW, SUITE 900 | WASHINGTON, DC 20036 | 202.827.7700 ISSUE BRIEF Gene Therapy in 2019: Milestones and Challenges or as long as medical researchers have been able to identify the genes responsible for particular KEY POINTS Fdiseases, they have set their sights on using that knowledge to devise gene therapies—ways to repair or Gene therapy research has yielded 10 circumvent the abnormal gene expression—to prevent approved treatments so far, and dozens or treat those diseases. What is the state of the science more are on the horizon. These therapies of gene therapy in 2019? What can we expect in the target both rare genetic diseases and more near future? And what gaps and challenges stand in the common diseases like some cancers. way of realizing our goals? Both research and clinical care face To address those questions, we reviewed the findings technological, ethical, and especially from completed trials of gene therapies and those financial challenges. ongoing trials that have completed recruitment. We also interviewed a diverse group of stakeholders, including Experts and stakeholders are exploring clinicians, pharmaceutical industry representatives, ways to tackle some of the most patients and patient advocates, government and private challenging issues, such as modifying insurers, and policy makers on the challenges and the approval process and how to pay important issues as well as their hopes for gene therapy. for treatment. This brief summarizes the findings of the report for policy makers. Gene Therapy Explained administered to patients directly (to modify cells in the body) or they may be transferred to a patient’s cells in the We define gene therapies as products that replace or lab with the modified cells then being transferred back to circumvent defective genes by a variety of mechanisms: the patient.
    [Show full text]
  • Pre-Certification Requirements for Procedures, Programs & Drugs
    Procedures, programs and drugs that require precertification Participating provider precertification list Starting August 1, 2020 Applies to the following plans (also see General information section #1-#4, #9-#10): Aetna® plans, except Traditional Choice® plans All health benefits and insurance plans offered and/or underwritten by Innovation Health plans, Inc., and Innovation Health Insurance Company, except indemnity plans, Foreign Service Benefit Plan, MHBP and Rural Carrier Benefit Plan All health benefits and health insurance plans offered, underwritten and/or administered by the following: Banner Health and Aetna Health Insurance Company and/or Banner Health and Aetna Health Plan Inc. (Banner|Aetna), Texas Health +Aetna Health Insurance Company and/or Texas Health+Aetna Health Plan Inc. (Texas Health Aetna), Allina Health and Aetna Health Insurance Company (Allina Health| Aetna), Sutter Health and Aetna Administrative Services LLC (Sutter Health | Aetna) aetna.com 23.03.882.1 I (8/20) Proprietary For additional information, read all general precertification information Providers may submit most precertification requests electronically through the secure provider website or using your Electronic Medical Record (EMR) system portal (See #1 in the General Information section for more information on precertification). Services that require precertification: 1. Inpatient confinements (except hospice) 18. Nonparticipating freestanding ambulatory For example, surgical and nonsurgical stays, surgical facility services, when referred stays in a skilled nursing facility or rehabilitation by a participating provider facility, and maternity and newborn stays that 19. Orthognathic surgery procedures, bone grafts, osteotomies and surgical exceed the standard length of stay (LOS) (See #5 management of the temporomandibular in the General Information section). joint 2.
    [Show full text]
  • MSM CH 1200 Draft 06-29-21
    MEDICAID SERVICES MANUAL TRANSMITTAL LETTER June 29, 2021 TO: CUSTODIANS OF MEDICAID SERVICES MANUAL FROM: JESSICA KEMMERER, HIPAA PRIVACY AND CIVIL RIGHTS OFFICER SUBJECT: MEDICAID SERVICES MANUAL CHANGES CHAPTER 1200 – PRESCRIBED DRUGS BACKGROUND AND EXPLANATION Revisions to Medicaid Services Manual (MSM) Chapter 1200 – Prescribed Drugs are being proposed to reflect recommendations approved on January 28, 2021 by the Drug Use Review (DUR) Board. The proposed changes include: Addition of new prior authorization criteria for Evrysdi® (risdiplam) within the new combined Spinal Muscular Atrophy (SMA) Agents section; addition of new prior authorization criteria for Vyondys 53® (golodirsen) within the new combined Duchenne Muscular Dystrophy (DMD) Agents section; Addition of new prior authorization criteria for Qutenza® (capsaicin); new prior authorization criteria for Fintepla® (fenfluramine) and lastly, technical changes to the Immunomodulator Drugs section to correct grammatical and inaccurate information. Throughout the chapter, grammar, punctuation and capitalization changes were made, duplications removed, acronyms used and standardized, and language reworded for clarity. Renumbering and re-arranging of sections was necessary. These changes are effective July 5, 2021. MATERIAL TRANSMITTED MATERIAL SUPERSEDED MTL OL MTL N/A MSM Chapter 1200 - Prescribed Drugs MSM Chapter 1200 - Prescribed Drugs Manual Section Section Title Background and Explanation of Policy Changes, Clarifications and Updates Appendix A Zolgenma® Revised section title
    [Show full text]
  • Measured Moments
    measured by moments 2019 ANNUAL REPORT OUR PROMISE. Rare diseases, real strides to treat them—this is why we’re here. No matter how uncommon the disorder, the life-limiting effects are a daily reality For those aFFected. When Stu Peltz Founded PTC over 20 years ago, he had this unique insight. That’s why we’re creating life-changing treatments every day. The Family Approach In Our DNA We are not simply there For you With every setback and on the rare disease journey, advance, we continue to push but we are with you, because forward every day because we know that family gets its this is not simply a job to us: strength from one another. it’s a calling. We’re in this together. Rare Resolve for The Science Rare Disease of Progress Our people choose to work here We use data and groundbreaking because they believe in the science in our search for moments that we build— progress—progress in in the labs and in the home. rare-disease treatments, of course, but also in the day-to-day lives of those affected. A Message to Our Shareholders Our exceptional team is well positioned to address whatever comes our way thanks to the progress we have made in past years. Stuart W. Peltz, Ph.D., PTC Therapeutics recently marked its We continue to invest in our clinical Chief Executive Ofcer 22nd anniversary, a proud moment stage programs and pipeline across for the company amid a diffcult our small molecule and gene time for all of us globally.
    [Show full text]